Sign in
Taking peopleNo phase

How uterine fibroids look on ultrasound during relugolix, estradiol and norethisterone treatment

Looks at ultrasound changes in fibroids of women taking relugolix, estradiol and norethisterone.

Key facts

Who runs it
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Where
Italy1 site in 1 countryChoose a country to see its sites
Trial code
Registry title
Ultrasound Transformation of Myomas During Relugolix-Estradiol-Norethisterone Treatment: The MySaturn Study
Status
Recruiting
People taking part
111 people, planned
Started
2 May 2025
Expected to end
2 May 2027
Type of study
Observational
Treatments tested
  • Relugolix/estradiol/norethisterone acetate
Record updated
17 August 2025

Who can take part

The trial is looking for women before menopause with benign uterine fibroids that cause abnormal uterine bleeding. They take relugolix/estradiol/norethisterone acetate by mouth, and the trial follows how the fibroids look on ultrasound.

Age
18 years and older
Sex
Women only
Disease stage
Before menopause. A non-cancerous lesion in the uterine muscle, seen on ultrasound. It causes symptoms such as heavy or irregular bleeding. The lesion must be larger than 10 mm.
Biomarker or test result
Ultrasound images must be available in digital format.
Main reasons for not taking part
  • Women after menopause, or women with fibroids that cause no symptoms
  • Ultrasound shows a lesion that may be cancer
  • Past cancer or pre-cancer of the uterus or cervix
  • Ovarian disease, or current treatment for another cancer
  • No digital ultrasound images, or images too poor to describe the lesion
Show the full registry criteria (15)Hide the full registry criteria

Who can take part

  • Age ≥ 18 years
  • Pre-menopausal status
  • Ultrasound diagnosis of benign myometrial lesion
  • Symptomatic patients presenting with abnormal uterine bleeding (menorrhagia/metrorrhagia)
  • Availability of ultrasound images in digital format

Who cannot take part

  • Myometrial formation suspected of malignancy on ultrasound (e.g., STUMP - Uterine Leiomyosarcoma)
  • Personal history of malignant or premalignant uterine neoplasia (e.g., STUMPs, leiomyosarcoma, atypical endometrial hyperplasia, endometrial carcinoma, cervical carcinoma)
  • Patients currently undergoing treatment for another malignancy
  • Age < 18 years
  • Patient refusal
  • Postmenopausal women
  • Myometrial lesion ≤ 10 mm
  • Asymptomatic patients with uterine fibromatosis
  • Patients with ovarian pathology
  • Patients lacking available digital ultrasound images or whose image quality is insufficient to adequately characterize the target lesion's ultrasound features

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Sex

This trial is currently available in Italy.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Uterine fibroids are benign tumors originating from the uterine muscle, affecting up to 70% of women by their 50s. Risk factors include African descent, nulliparity, obesity, and diabetes. While many fibroids are asymptomatic, 25-50% of affected women experience symptoms like heavy menstrual bleeding, pelvic pain, and pressure-related issues. Accurate diagnosis and differentiation from rare malignant tumors (e.g., uterine sarcomas) remain challenging, particularly before surgery.

Read full original descriptionShow less

Ultrasound is the first-line tool for evaluating fibroids, with specific features (e.g., shape, vascularity) helping distinguish benign from suspicious lesions. The MUSA guidelines standardize ultrasound terminology for myometrial assessments. Current treatment options vary based on symptoms and malignancy risk. Among pharmacologic options, the combination of relugolix, estradiol, and norethisterone has shown efficacy in reducing bleeding and pain in symptomatic fibroids, with a favorable safety profile. However, its impact on fibroid morphology and ultrasound appearance is not yet well understood.

The group in the trial

  • Uterine fibroids symptomatic for abnormal uterine bleeding

    Patients with ultrasound diagnosis of uterine fibroids, symptomatic for abnormal uterine bleeding, eligible for oral medical therapy with relugolix/estradiol/norethisterone

    Treatment: Relugolix/estradiol/norethisterone acetate

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
MyomaS Aspect Transformation at Ultrasound During Relugolix Estradiol Noretisterone Treatment: MySaturn Study
Plain-language title
How uterine fibroids look on ultrasound during relugolix, estradiol and norethisterone treatmentGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Criteria questions
Built from NCT06953076, who can take part
Record updated
17 August 2025